Pyxis Oncology, Inc. Comprehensive Income
Pyxis Oncology, Inc. (PYXS) reported Comprehensive Income of -$25.35 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-13
- Pyxis Oncology, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$25.35M.
- Pyxis Oncology, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$23.32M.
- Pyxis Oncology, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$18.12M.
- Pyxis Oncology, Inc. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$21.93M.
- Pyxis Oncology, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$79.74M.
- Pyxis Oncology, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was -$77.22M.
- Pyxis Oncology, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$73.73M.
- Pyxis Oncology, Inc. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$120.72M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$25.35M 10-Q · filed 2026-08-13 | -$48.67M 10-Q · filed 2026-08-13 | -$66.80M derived: sum of 3 quarters · filed 2026-08-13 | -$88.73M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$23.32M 10-Q · filed 2026-05-14 | -$41.45M derived: sum of 2 quarters · filed 2026-05-14 | -$63.38M derived: sum of 3 quarters · filed 2026-05-14 | -$81.78M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$18.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$40.05M derived: sum of 2 quarters · filed 2026-03-23 | -$58.46M derived: sum of 3 quarters · filed 2026-08-13 | -$79.74M 10-K · filed 2026-03-23 |
| 2025-09-30 | -$21.93M 10-Q · filed 2025-11-03 | -$40.34M derived: sum of 2 quarters · filed 2026-08-13 | -$61.62M 10-Q · filed 2025-11-03 | -$97.37M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$18.41M 10-Q · filed 2026-08-13 | -$39.69M 10-Q · filed 2026-08-13 | -$75.44M derived: sum of 3 quarters · filed 2026-08-13 | -$96.19M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$21.28M 10-Q · filed 2026-05-14 | -$57.03M derived: sum of 2 quarters · filed 2026-05-14 | -$77.78M derived: sum of 3 quarters · filed 2026-05-14 | -$95.12M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$35.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-23 | -$56.50M derived: sum of 2 quarters · filed 2026-03-23 | -$73.84M derived: sum of 3 quarters · filed 2026-03-23 | -$77.22M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$20.75M 10-Q · filed 2025-11-03 | -$38.09M derived: sum of 2 quarters · filed 2025-11-03 | -$41.47M 10-Q · filed 2025-11-03 | -$56.90M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | -$17.34M 10-Q · filed 2025-08-14 | -$20.72M 10-Q · filed 2025-08-14 | -$36.15M derived: sum of 3 quarters · filed 2025-08-14 | -$59.22M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | -$3.38M 10-Q · filed 2025-05-15 | -$18.81M derived: sum of 2 quarters · filed 2025-05-15 | -$41.88M derived: sum of 3 quarters · filed 2025-05-15 | -$58.56M derived: sum of 4 quarters · filed 2025-05-15 |
| 2023-12-31 | -$15.43M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | -$38.50M derived: sum of 2 quarters · filed 2025-03-18 | -$55.18M derived: sum of 3 quarters · filed 2025-03-18 | -$73.73M 10-K · filed 2025-03-18 |
| 2023-09-30 | -$23.07M 10-Q · filed 2024-11-12 | -$39.75M derived: sum of 2 quarters · filed 2024-11-12 | -$58.30M 10-Q · filed 2024-11-12 | -$94.40M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$16.68M 10-Q · filed 2024-08-14 | -$35.23M 10-Q · filed 2024-08-14 | -$71.33M derived: sum of 3 quarters · filed 2024-08-14 | -$99.00M derived: sum of 4 quarters · filed 2024-08-14 |
| 2023-03-31 | -$18.55M 10-Q · filed 2024-05-14 | -$54.65M derived: sum of 2 quarters · filed 2024-05-14 | -$82.32M derived: sum of 3 quarters · filed 2024-05-14 | -$107.88M derived: sum of 4 quarters · filed 2024-05-14 |
| 2022-12-31 | -$36.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$63.77M derived: sum of 2 quarters · filed 2024-03-21 | -$89.34M derived: sum of 3 quarters · filed 2024-03-21 | -$120.72M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$27.67M 10-Q · filed 2023-11-07 | -$53.24M derived: sum of 2 quarters · filed 2023-11-07 | -$84.62M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | -$25.56M 10-Q · filed 2023-08-11 | -$56.94M 10-Q · filed 2023-08-11 | ||
| 2022-03-31 | -$31.38M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |